Predictive and Prognostic Relevance of p53 in Patients With Serous Epithelial Ovarian Cancer

Document Type : Original Article

Authors

1 Clinical oncology, Mansoura university, Dakahleyia, Egypt

2 Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Mansoura University Egypt

3 department of Pathology, Faculty of Medicine, Mansoura University, Egypt

Abstract

Background:  Ovarian cancer is a common malignant gynecological tumor that is difficult to diagnose early, progresses rapidly, and causes high mortality. Aims of our study: to assess the relationship of P53 with other clinico-pathological parameters and the effect of P53 on patients’ out-come.
Subjects and methods: This study was conducted at Clinical Oncology and Nuclear Medicine Department  with Pathology Department, Faculty of Medicine, Mansoura University. The study was carried out on 50 patients with serous epithelial ovarian cancer presented to receive adjuvant treatments following a primary surgery and were followed from the first day after surgery, follow-up started on January, 2012 till February, 2016. P53 expression was assessed immunohistochemically on formalin-fixed paraffin-embedded tissues, and Secondary red Envision system. Patients were given adjuvant treatment(s) according to according to NCCN guidelines. The primary endpoint of the study was loco regional recurrence, and distant metastasis. At the end of the follow-up period, the patient clinico-pathological data and patient outcome were collected.
Results: we found that p53 negative tumors  have a better OS & DFS at 3 year than with P53 positive tumors, but not reached statistically significant differences ( p value = 0.98 & 0.48 respectively).
Conclusion: Our results showed no statically significant difference between p53 expression. OS & DFS, need to be evaluated in other study including large number of patients before using it as a marker for the outcome in these tumors.

Files

Share

How to cite

Statistics